News
8.9.22

TOPADUR has been selected as a TOP 100 Scale-up 2022 with unicorn potential

TOPADUR Pharma AG has been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team, supporters, and partners believing in us along the way!

Please check out the link below.

Download DocumentDokument herunterladenhttps://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most-promising-scaleups-in-2022
15.10.21
Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

Read more
27.10.20
News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

Read more
3.7.20
Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

Read more